Margalit E. Rosenkranz, MD
- Assistant Professor of Pediatrics
Margalit Rosenkranz, MD, joined the Division of Rheumatology in 2004. She brings a strong background in research focused on developing a deeper understanding of the immunogenetics of juvenile rheumatoid arthritis (JRA) and other rheumatic diseases.
Rosenkranz earned a bachelor's degree in biology at the University of Pittsburgh in 1994 and her medical degree at the University of Pittsburgh Schoolof Medicine in 1998. She completed her pediatric residency at New York University Medical Center and Bellevue Hospital in 2001 and completed a pediatric rheumatology fellowship at the Hospital for Special Surgery and Weill Medical College of Cornell University in New York in 2004.
At Children's Hospital, Rosenkranz's research has focused on proteomics in JRA to identify specific protein profiles of a patient. By identifying the proteomic "fingerprint" of a patient and differentially expressed proteins in the various subtypes of juvenile rheumatoid arthritis, she is seeking to determine whether the serum proteome signatures vary among the different forms of JRA. Proteomic signatures also may be useful in identifying patients who are more orless likely to respond to specific treatments. She received an NIH K23 grant to support her research activities. She is involved in and oversees various clinical research studies in the division of rheumatology including international registries and industry sponsored drug studies.
Professional and Scientific Society Memberships
- Pediatric Rheumatology Collaborative Study Group, 2008-Present
- Childhood Arthritis and Rheumatology Research Alliance, 2007-Present
- American College of Rheumatology, Fellow, 2001-Present
- American Academy of Pediatrics, Fellow, 2001-2014
- American Medical Student Association, 1994-1998
Education & Training
- BS, Biology, University of Pittsburgh, 1994
- MD, University of Pittsburgh, 1998
- Internship in Pediatrics, NYU Medical Center/Bellevue Hospital, 1998-1999
- Residency in Pediatrics, NYU Medical Center/Bellevue Hospital, 1999-2001
- Fellowship in Pediatric Rheumatology, Hospital for Special Surgery/Weill Medical School of Cornell University, 2001-2004
Mallalieu NL, Wimalasundera S, Hsu JC, Douglass W, Wells C, Penades IC, Cuttica R, Huppertz HI, Joos R, Kimura Y, Milojevic D, Rosenkranz M, Schikler K, Constantin T, Wouters C. Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial. Pediatric Rheumatology, 2019 Aug , 7:57.
Ferguson ID, Driffin P, Michel JJ, Yano H, Gaffen SL, Mueller RG, Dvergsten JA, Pianelli JD, Rosenkranz ME, Kietz DA, Vallejo AN. T Cell Receptor-Independent, CD31/IL-17A-Driven Inflammatory Axis Shapes Synovitis in Juvenile Idiopathic Arthritis. Front Immunol 2018 Aug 6;9:1802.
Ramgopal S, Rosenkranz M, Nowalk AJ, Zucherbraun, NS. Sternoclavicular Arthritis as a Clinical Presentation for Lyme Disease. Pediatrics. 2018 April; 141(s5):S466.
Moncrieffe H, Bennett MF, Tsoras M, Luyrink LK, Johnson AL, Xu H, Dare, J, Becker ML, Prahalad S, Rosenkranz M, O’Neill KM, Nigrovic PA, Griffin TA, Lovell DJ, Grom AA, Thompson SD. Transcriptional profiles of JIA patient blood with subsequent poor response to methotrexate. Rheumatology, 2017 Aug: Volume 56 (9): 1542–1551.
Ferguson I, Griffin P, Michel J, Kietz D, Rosenkranz M, de Vallejo A. TCR-independent activation of T-cells through CD31 triggering as an etiology of cytokine production in juvenile idiopathic arthritis (JIA). J Immunol, 2014 May; Volume 192 (1), 184.20
Dvergsten JA, Mueller RG, Griffin P, Abedin S, Pishko A, Michel JJ, Rosenkranz ME, Reed AM, Kietz DA, Vallejo AN. 2013. Premature cell senescence and T cell receptor-independent activation of CD8T cells in juvenile idiopathic arthritis. Arthritis Rheum, 2013 Aug;65(8):2201-10.
Morishita K, Li SC, Muscal E, Spalding S, Guzman J, Uribe A, Abramson L, Baszis K, Benseler S, Bowyer S, Campillo S, Chira P, Hersh AO, Higgins G, Eberhard A, Ede K, Imundo L, Jung L, Kim S, Kingsbury DJ, Klein-Gitelman M, Lawson EF, Lovell DJ, Mason T, McCurdy D, Nanda K, Nassi L, O'Neil KM, Rabinovich E, Ramsey SE, Reiff A, Rosenkranz M, Schikler K, Stevens A, Wahezi D, Cabral DA. Assessing the performance of the Birmingham Vasculitis Activity Score at diagnosis for children with antineutrophil cytoplasmic antibody-associated vasculitis in A Registry for Childhood Vasculitis (ARChiVe). J Rheumatol 2012, 39(5):1088-94.
Uribe AG, Huber AM, Kim S, O'Neil KM, Wahezi DM, Abramson L, Baszis K, Benseler SM, Bowyer SL, Campillo S, Chira P, Hersh AO, Higgins GC, Eberhard A, Ede K, Imundo LF, Jung L, Kingsbury DJ, Klein-Gitelman M, Lawson EF, Li SC, Lovell DJ, Mason T, McCurdy D, Muscal E, Nassi L, Rabinovich E, Reiff A, Rosenkranz M, Schikler KN, Singer NG, Spalding S, Stevens AM, Cabral DA. Increased Sensitivity of the European Medicines Agency Algorithm for Classification of Childhood Granulomatosis with Polyangiitis. J Rheumatol. 2012, 39:1687-1697.
Morishita K, Guzman J, Chira P, Muscal E, Zeft A, Klein-Gitelman M, Uribe AG, Abramson L, Benseler SM, Eberhard A, Ede K, Hashkes PJ, Hersh AO, Higgins G, Imundo LF, Jung L, Kim S, Kingsbury DJ, Lawson EF, Lee T, Li SC, Lovell DJ, Mason T, McCurdy D, O'Neil KM, Punaro M, Ramsey SE, Reiff A, Rosenkranz M, Schikler KN, Scuccimarri R, Singer NG, Stevens AM, van Mater H, Wahezi DM, White AJ, Cabral DA. Do Adult Disease Severity Subclassifications Predict Use of Cyclophosphamide in Children with ANCA-associated Vasculitis? An Analysis of ARChiVe Study Treatment Decisions. J Rheumatol. 2012, 39:2012-20.
Rosenkranz ME, Wilson DC, Marinov AD, Decewicz A, Grof-Tisza P, Kirchner, D, Giles B, Reynolds PR, Kolli K, Liebman MN, Thompson SD, Hirsch R. Synovial Fluid Proteins Differentiate Between the Subtypes of Juvenile Idiopathic Arthritis. Arthritis Rheum 2010 62(6):1813-1823.
Academic and Research Interests
- Overseeing clinical research studies including research registries and industry sponsored studies
M15-340, An Open-Label Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects with Polyarticular Course Juvenile Idiopathic Arthritis, 2019-Present, Abbvie, $122,604
A3921165, Efficacy, safety, tolerability and pharmacokinetics of Tofacitinib for Treatment of Systemic Juvenile Idiopathic Arthritis (SJIA) with active systemic features in children and adolescent subjects, 2018-Present, Pfizer, $24,905/patient
Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry (included sub studies of FROST, STOP JIA, JDM, SLE, PROMOTE and Ultrasound), CARRA Registry (Childhood Arthritis and Rheumatology Research Alliance), initial enrollment: $216, subsequent visits: $81